Data are available from the Mendeley database: (<https://data.mendeley.com/datasets/zwsg6z5p8d/1>), (DOI: [10.17632/zwsg6z5p8d.1](https://doi.org/10.17632/zwsg6z5p8d.1))

1 Introduction {#sec001}
==============

Naproxen is a non-steroidal anti-inflammatory drug of the propionic acid class widely used to manage chronic and acute pain, fever, swelling, and inflammation. Recently, a combination with esomeprazole has been introduced to the market to prevent gastrointestinal adverse reactions \[[@pone.0236297.ref001]--[@pone.0236297.ref003]\].

Naproxen ((S)-2-(6-methoxynaphthalen-2-yl)propanoic acid)is mainly metabolized by hydroxylation, forming 6-O-desmethylnaproxen, which then conjugates with glucuronic acid. Esomeprazole ((R)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo\[d\]imidazole) is the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted to the active achiral sulfonamide \[[@pone.0236297.ref004]\]. Several analytical methods have been developed to determine the concentrations of naproxen and 6-desmethylnaproxen using liquid chromatography--tandem mass spectrometry (LC-MS/MS) \[[@pone.0236297.ref005], [@pone.0236297.ref006]\], but none in saliva samples.

To study the pharmacokinetics (PK) of naproxen alone and in combination with esomeprazole in saliva samples and predict its functionality in cases of acute pain owing to delayed absorption, saliva samples will be collected several times after the administration of one pill of naproxen (500 mg) and naproxen combined with esomeprazole (500 mg + 20 mg), and concentrations of naproxen and its major metabolite 6-O-desmethylnaproxen will be determined. The use of saliva for PK tests makes collection simpler and more secure, without the need for a professional and with greater adherence to the study. Therefore, the aim of the present study was to disseminate the results of robust and reliable PK studies.

Additionally, the detection and quantification of naproxen and its metabolite will be validated to determine the PKs of this drug, thereby contributing to the development of a proper prescription for different medical and dental interventions that cause acute pain. The hypothesis of the present study is that the absorption of naproxen, when administered with esomeprazole, is slower than that when administered alone. Thus, the results of the study can be used to reassess the use of naproxen for pain control after medical and dental interventions that cause acute pain.

2 Material and methods {#sec002}
======================

This project was approved by the Research Ethics Committee of the Bauru School of Dentistry/University of São Paulo (CAAE 49806115.0.0000.5417), registered in ClinicalTrials.gov (NCT03092193). All volunteers participating in this research will be fully informed about the project's content and procedures and sign a consent form.

2.1 Chemicals and reagents {#sec003}
--------------------------

Naproxen, 6-O-desmethylnaproxen, esomeprazole, and piroxicam (internal standard, IS) were purchased from Sigma-Aldrich (São Paulo, Brazil). Methanol, ammonium acetate, and other chromatographic grade chemicals used in the tests were purchased from Merck (Hohenbrunn, Germany). During all experiments, water from a Milli-Q Plus purification system (Millipore, Belford, MA, USA) was used.

2.2 Preparation of standard solutions {#sec004}
-------------------------------------

Stock solutions of naproxen (1 mg/mL methanol), 6-O-desmethylnaproxen (1 mg/mL methanol), esomeprazole (500 μg/mL methanol), and IS (1 mg/mL methanol) were prepared. A dilution series from each stock solution (10 μg/mL)was used to construct standard curves. When not in use, solutions were stored in the dark at -20°C and all stages of the research were conducted under a sodium vapor lamp to avoid photodecomposition of naproxen, 6-O-desmethylnaproxen, esomeprazole, and the IS \[[@pone.0236297.ref007], [@pone.0236297.ref008]\].

2.3 LC-MS/MS {#sec005}
------------

The concentrations of naproxen and its major metabolic, 6-O-desmethylnaproxen, were analyzed using an 8040 Triple Quadrupole Mass Spectrometer (Shimadzu, Kyoto, Japan)and piroxicam was used as an IS. Before performing the standard curve for naproxen, 6-O-desmethylnaproxen, esomeprazole, and the IS, the mobile phase was standardized to increase the reliability of the results that will be obtained from saliva samples in the PK studies \[[@pone.0236297.ref007]\]. As naproxen and esomeprazole ionize in different ways, only the PKs of naproxen and its major metabolite were investigated, as these are the drugs of most interest for pain control.

Initial analysis for drug characterization was performed by LC-MS/MS and separation was performed using a Shim-Pack XR-ODS 75Lx2.0 column and C18 pre-column (Shimadzu, Kyoto, Japan) at 40°C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v) with an injection flow of 0.3 mL/min. The total analytical run time was 5 min.

The chromatographic effluent was directed to the 8040 Triple Quadrupole Mass Spectrometer (Shimadzu, Kyoto, Japan). Mass spectrometry was performed following the information obtained in the optimization of ions in positive/negative ionization mode using ionizing electrospray, with monitored selection for quantitative analysis. The voltage of the ionization electrospray capillary was 4.5 kV. Source and desolvation temperatures were maintained at 250°C and 350°C, respectively. Nitrogen was used as the mist gas at 3.0 L/min and argon gas as the collision gas at approximately 230 kPa. The cone voltage was defined for each transition and drug molecular ions were fragmented by the variable collision energy. All conditions were achieved by the direct injection of standard drug solutions of naproxen and 6-O-desmethylnaproxen without the separation column, resulting in transitions in which specific father/son ions were employed. The time of analysis for each event was 0.075 ms. The measurements were performed in multiple reaction monitoring mode to quantify the transitions presented in [Fig 1](#pone.0236297.g001){ref-type="fig"}. The peak areas for all components were integrated automatically using the LabSolutions software, version 5.97(Shimadzu, Kioto, Japan). The transitions considered for the quantification and qualification of the peaks are shown in [Table 1](#pone.0236297.t001){ref-type="table"}.

![Multiple reaction monitoring mode to quantify the naproxen, 6-O-desmethylnaproxen, and piroxicam transitions.](pone.0236297.g001){#pone.0236297.g001}

10.1371/journal.pone.0236297.t001

###### Quantifier and qualifier product ions used in the analysis.

![](pone.0236297.t001){#pone.0236297.t001g}

  ------------------------- -------------------------------------------------------- ----------- ----------- -------------------
  **O-Desmethylnaproxen**                                                                                    
  **Type**                  **m/z**                                                  **Inten**   **Act %**   **Idenf. Rang %**
  T                         214.900\>171.250[^a^](#t001fn001){ref-type="table-fn"}   199246      100.00      100%
  Ref 1                     214.900\>169.250[^b^](#t001fn002){ref-type="table-fn"}   49605       24.90       \-
  Ref 2                     214.900\>143.050                                         3283        1.65        \-
  **Naproxen**                                                                                               
  **Type**                  **m/z**                                                  **Inten**   **Act %**   **Idenf. Rang %**
  T                         228.900\>170.30[^a^](#t001fn001){ref-type="table-fn"}    513749      100.00      100%
  Ref 1                     228.900\>169.250[^b^](#t001fn002){ref-type="table-fn"}   336855      65.57       \-
  Ref 2                     228.900\>185.200[^b^](#t001fn002){ref-type="table-fn"}   288128      56.08       \-
  **Piroxicam**                                                                                              
  **Type**                  **m/z**                                                  **Inten**   **Act %**   **Idenf. Rang %**
  T                         331.900\>95.100[^a^](#t001fn001){ref-type="table-fn"}    33688       100.00      100%
  Ref 1                     331.900\>121.050                                         15274       45.37       \-
  Ref 2                     331.900\>78.100[^b^](#t001fn002){ref-type="table-fn"}    23870       70.90       \-
  ------------------------- -------------------------------------------------------- ----------- ----------- -------------------

^a^Quantifier: the most intense peak.

^b^Qualifier: a second peak (SRM)t has been used as a qualifier for the same analysis.

2.4 Sample preparations {#sec006}
-----------------------

Drug-free saliva blanks (400 μL) were enriched with 5 ng of IS + 6.25 ng of naproxen and 6-O-desmethylnaproxen and 400 μL of 0.5 M HCl for the first calibration standard point. For the standard calibration curve, eight serial dilutions were performed and the final mass was equal to 0.024 ng of naproxen and 6-O-desmethylnaproxen. The IS mass was the same for all curve points. These standard calibration curve points were extracted with 2 mL of ethyl acetate in 15 mL polypropylene tubes, shaken vigorously for 15 min at high speed (Heidolph Multi Reax EU, Heidolph Instruments GmbH & Co., KG, Schawaback, Germany) and centrifuged at 2,500 g at 4°C for 10 min. The organic phase (\~1.8 mL) was then transferred and evaporated under airflow at room temperature in the chamber.

Saliva samples before naproxen alone and naproxen with esomeprazole intake (t = 0) were analyzed to ensure that there was no interference. After evaporation, the residues were dissolved in 100 μL methanol:10 mM ammonium acetate (70:30, v/v, isocratic), vortexed for 1 min, transferred to inserts, and then 5 μL of this solution was used for high-performance liquid chromatography.

2.5 Volunteer sample preparation {#sec007}
--------------------------------

The PK study of naproxen and its major metabolite, 6-O-desmethylnaproxen, will be performed in six healthy volunteers, who will have sequential collections of saliva before and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6 8, 11, 24, 48, 72, and 96 h after the ingestion of a naproxen tablet (500 mg) and esomeprazole-associated naproxen tablets (500 + 20 mg), at two different times, separated by 1--2 months. Samples will be centrifuged for 10 min (2,500 rpm) and the supernatant stored at -20°C until analysis.

The quantified PK parameters of naproxen and its major metabolite, 6-O-desmethylnaproxen, in saliva, alone and in combination with esomeprazole, will be estimated using the mean area under the curve, 0--72 h (AUC~0-72~)and AUC~infinity~, predicted total clearance (Clt/F), volume of distribution (Vd/F), and elimination half-life (t~1/2~) based on concentrations obtained experimentally using a non-compartmental model with first-order elimination. These PK analyses will be performed using Phoenix WinNonlin® 8.1 software (Pharsight Corp., Mountain View, CA, USA). The data will be presented as mean ± standard deviation.

2.6 PK from six volunteers {#sec008}
--------------------------

In addition to validating the method for the detection and quantification of naproxen and its metabolite, 6-O-desmethylnaproxen, the PKs of six volunteers who will take one pill of naproxen (500 mg) and naproxen associated with esomeprazole (500 mg + 20 mg) will be investigated.

This study was registered as a clinical trial at ClinialTrials.gov (NCT030902193) after the analysis carried out by the website, as when prescribing these two drugs (naproxen alone and naproxen in combination with esomeprazole), a series of side effects may occur in a small portion of the population, such as allergies, gastric irritation, intestinal irritation, gastritis, colitis, and gastrointestinal bleeding. Such reports will be noted and analyzed during the clinical trial.

2.7 Analytical validation {#sec009}
-------------------------

The methodology for analyzing naproxen and 6-O-desmethylnaproxen in human saliva samples will be validated for essential parameters, such as residual effect and matrix effects, calibration curve, selectivity, precision, accuracy, stability, and dilution in accordance with the current guidelines of the United States Food and Drug Administration (October 2018) for bioanalytical methods to ensure reliability of the results obtained from the PK assays in human saliva.

Quality controls (QCs) for human saliva will be prepared by the addition of the final working solutions of treatment saliva to drug-free human saliva. Based on the lower limit of quantification (LLOQ), low-quality control (LQC), medium-quality control (MQC), and high-quality control (HQC) samples will be prepared. The QCs will be prepared, aliquoted (400 μL enriched saliva) in polypropylene tubes, and stored at −20°C until analysis. For residual effect evaluation, injections of the blank sample before and after the injection of the HQC sample will be analyzed. The chromatogram of the white sample obtained after HQC injection will be compared with the sample chromatogram of the LLOQ. The residual effect will be considered absent when the areas of interfering peaks eluted in the retention time of the analytes are less than 20% of the LLOQ and less than 5% of the IS area.

The matrix effect in the saliva will be evaluated using samples from six drug-free volunteers. Blank saliva samples from healthy volunteers will be obtained from the Laboratory of Clinical Pharmacology and Physiology, School of Dentistry, Bauru/USP. The matrix effect will be determined by comparing the peak areas obtained from naproxen, 6-O-desmethylnaproxen, and IS directly to the mobile phase (no matrix) with the peak in the presence of a matrix (white samples added to standard solutions of naproxen, 6-O-desmethylnaproxen, and IS after extraction). The normalizing factor of the IS in the matrix will be calculated for each sample matrix by dividing the ratio of the analyte by the response of the IS in the absence of the matrix. The coefficient of variation for the normalized IS must be less than 15%. Samples will be analyzed between the LQC and the HQC.

The saliva calibration curve will be prepared using the following concentrations in polypropylene tubes: 2500, 1250, 625, 312.5, 156.2, 78.1, 39.1, 19.5, 9.8, 4.9, and 2.4 ng/mL of naproxen and 6-O-desmethylnaproxen, plus a blank sample (no analyte and no IS) and a zero sample (IS only). Linear regression equations and correlation coefficients will be used from the ratios of the standard peak areas: IS plotted against the saliva samples used. Calibration curves will be plotted using the various concentrations of the IS versus the respective areas of their peaks, plotted as a linear regression line. Calibration curves will be approved when deviations of at least 75% of the calibration standards are less than or equal to 20% for LQC and 15% for other standards.

The LLOQ is defined as the lowest concentration of naproxen and 6-O-desmethylnaproxen quantified in saliva with acceptable precision and accuracy. The analyte interfering peaks at the retention time should be \<20% of the analyte in the samples. To obtain the LLOQ, samples with the lowest detected concentration of naproxen, 6-O-desmethylnaproxen, and the IS in saliva will be evaluated ten times.

Three calibration curves for the analysis of naproxen and 6-O-desmethylnaproxen will be performed using aliquots of 400 μL of saliva containing a blank sample (no drug and no IS), one processed (IS added), and eight enriched with 25 μL standards of naproxen, 6-O-desmethylnaproxen, and IS, subjected to extraction and analysis procedures. The linearity will be evaluated using a linear mathematical model using the weighted equation 1/χ2.

Accuracy and precision will be evaluated in a single assay (intra-assay) and three different assays (inter-assay, in three different periods). Five replicates of each assay were used for LLOQ, LQC, MQC, and HQC. Precision is expressed as a coefficient of variation (%) and accuracy by relative standard deviation (RSD), which must be between 15% and 20% (more tolerant) of the nominal value.

Naproxen and 6-O-desmethylnaproxen stabilities in saliva were measured using the LQC and HQC, analyzed in triplicate after preparation, and stored under different conditions (after short-term stability, post-processing stability, and three cycles of freezing and thawing). The concentrations of the samples will be interpolated with a recently prepared calibration curve. Samples will be considered stable when concentrations are within 15% of the nominal value. Additionally, samples in saliva will be added to create a concentration greater than the calibration curves for naproxen and 6-O-desmethylnaproxen. Then, this will be diluted five times to obtain a dilution integrity QC (DQC).

2.8 Statistical analysis {#sec010}
------------------------

After analyzing the PK and pharmacodynamic results using the Phoenix WinNonlin software (version 8.1), the data will be organized descriptively and a paired *t-*test will be performed to compare naproxen absorption after volunteers are administered, at two different times, naproxen alone or naproxen in combination with esomeprazole.

10.1371/journal.pone.0236297.r001
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Reviewer \#1: This manuscript does not appear complete, as there are no analyses, results, or discussion sections. It appears to only be a partly-developed protocol as there is no mention of any planned statistical analyses for the data collected from 17 time points. This needs to be amended, and results should be shown if it is to be a true P/K study.

Additionally, it is mentioned that time point 0 for each drug were analyzed to ensure no interference, but there is no mention of how this analysis was performed.

Answer: Thank you for your observation. The statistical analyses, which we intend to use, were added in the method section. Our article type is Registered Report Protocol, therefore, the results will be presented in the second manuscript as well as the discussion. The time point 0 refers to the collection of saliva from the volunteers before taking the medications. In fact, this collection is important to ensure that the pre-determined methods of detecting the drugs under study do not detect other molecules in the volunteers\' saliva.

Reviewer \#2: The submission was not complete as only the abstract, introduction and methods were provided. Despite this, the following major issues were identified which must be addressed in the complete version:

• The method is intended for a clinical application among patients. Method validation is a must- it is not optional when dealing with patient samples. There was no mention of method validation. The authors must completely validate the method as per regulatory guidelines, the FDA, EMA or ICH.

Answer: Thank you for your observation. Our article type is Registered Report Protocol, therefore, the results will be presented in the second manuscript as well as the discussion (if this manuscript is able to be accepted). We will we will execute the validations in all analyzes carried out in accordance with the FDA Please find the description of the experiments for validation in the methods section.

• Though the authors indicate that this is the first time a method is reported for Saliva, did they attempt the conditions of the reported methods measuring the same compounds. Is there any similarities or improvements form an analytical stand point?

Answer: Thank you for your question. Yes, we did a research where we compared the detection and quantification of Piroxicam in saliva and plasma. These results confirmed that in saliva it is possible to perform pharmacokinetic tests as in plasma (Calvo et al. J Pharm Biomed Anal. 2016 Feb 20;120:212-20. doi: 10.1016/j.jpba.2015.12.042).

• Patient sample preparation \[containing the drug\] was not adequately described.

Answer: Thank you for your observation. We adequately described patient sample preparation. Please find this new information in method section.

• PK studies are usually done in plasma- what information we can get from a Saliva for a medication intended for pain. Clarification and justification are needed to justify publication.

Answer: Thank you for your question. The idea of the study is to share the experience that it is possible to perform pharmacokinetic tests, using saliva, of any drug, including anti-inflammatory drugs. Pharmacokinetic studies are important for planning treatment according to the speed of metabolism of each person. This information was added in the introduction.

• What is the structures of the drugs and their monitored product ions? MSMS data should be shown along with the proposed structures. Why these specific product ions were chosen?

Answer: Thank you for your observation. Our mass spectrometer, based on the reported drug mass, automatically optimizes all parameters including product ions, which can be seen in Table 1.

• Did the authors monitor the ratios of the quantifier/qualifier ions? A must when doing quantification with LC-MS/MS to ensure peak purity.

Answer: Thank you for your observation. These information is in the new table 2.

Table 2: Quantifier and qualifier product ion to be used in analysis.

O-Desmethylnaproxen

Type m/z Inten Act % Idenf. Rang %

T 214.900\>171.250a 199246 100.00 100%

Ref 1 214.900\>169.250b 49605 24.90 -

Ref 2 214.900\>143.050 3283 1.65 -

Naproxen

Type m/z Inten Act % Idenf. Rang %

T 228.900\>170.30a 513749 100.00 100%

Ref 1 228.900\>169.250b 336855 65.57 -

Ref 2 228.900\>185.200b 288128 56.08 -

Piroxicam

Type m/z Inten Act % Idenf. Rang %

T 331.900\>95.100a 33688 100.00 100%

Ref 1 331.900\>121.050 15274 45.37 -

Ref 2 331.900\>78.100b 23870 70.90 -

aQuantifier - the most intense peak

bQualifier - a second peak (SRM)t have used as a qualifier for the same analysis

• In fact, it was not clear which product ion was the quantifier and which one is the qualifier

Answer: Thank you for your observation. Please check the answer above.

• The authors mention molecular ions. I think the authors mean protonated ions as molecular ions are the radical cations and it is not commonly seen in ESI.

Answer: Thank you for your observation. Sorry for the mistake. In fact we refer to the protonated ions.

• Why a structural analogue was used for internal standard instead of isotopically labelled IS.

Answer: Thank you for your question. Previous studies by our group have shown that Piroxicam could be used successfully as an internal standard. However, we have the conscience and the intention to start using the isotopically labeled IS. During the validation process, we will guarantee that there will be no interference from the chosen IS.
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We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:
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